[Federal Register Volume 62, Number 204 (Wednesday, October 22, 1997)]
[Notices]
[Page 54857]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-27896]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacture of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 4, 1997, Novartis 
Pharmaceuticals Corp., Attn: Compliance, East Hanover, 556 Morris 
Avenue, Summit, New Jersey 07901, made application by renewal to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of the Schedule II controlled substance methylphenidate 
(1724).
    The firm plans to manufacture the finished product for distribution 
to its customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, D.C. 20537, Attention: DEA Federal Register Representative 
(CCR), and must be filed no later than December 22, 1997.

    Dated: October 6, 1997.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 97-27896 Filed 10-21-97; 8:45 am]
BILLING CODE 4410-09-M